EP3469069A4 - COMPOSITIONS AND METHODS WITH B-LYMPHOZYT CELL LINE EXPRESSING A DIFFERENT MEMBRANE IMMUNIZATION LOBULIN AS SECRETIED IMMUNOGLOBULIN, AND CYTOLYSIS FUNCTION - Google Patents

COMPOSITIONS AND METHODS WITH B-LYMPHOZYT CELL LINE EXPRESSING A DIFFERENT MEMBRANE IMMUNIZATION LOBULIN AS SECRETIED IMMUNOGLOBULIN, AND CYTOLYSIS FUNCTION Download PDF

Info

Publication number
EP3469069A4
EP3469069A4 EP17811004.5A EP17811004A EP3469069A4 EP 3469069 A4 EP3469069 A4 EP 3469069A4 EP 17811004 A EP17811004 A EP 17811004A EP 3469069 A4 EP3469069 A4 EP 3469069A4
Authority
EP
European Patent Office
Prior art keywords
secretied
lymphozyt
lobulin
immunoglobulin
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17811004.5A
Other languages
German (de)
French (fr)
Other versions
EP3469069A1 (en
Inventor
Roderick A. Hyde
Wayne R. Kindsvogel
Gary L. Mcknight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invention Science Fund II LLC
Original Assignee
Kota Biotherapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/178,715 external-priority patent/US10233424B2/en
Application filed by Kota Biotherapeutics LLC filed Critical Kota Biotherapeutics LLC
Publication of EP3469069A1 publication Critical patent/EP3469069A1/en
Publication of EP3469069A4 publication Critical patent/EP3469069A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP17811004.5A 2016-06-10 2017-06-08 COMPOSITIONS AND METHODS WITH B-LYMPHOZYT CELL LINE EXPRESSING A DIFFERENT MEMBRANE IMMUNIZATION LOBULIN AS SECRETIED IMMUNOGLOBULIN, AND CYTOLYSIS FUNCTION Withdrawn EP3469069A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/178,715 US10233424B2 (en) 2011-12-22 2016-06-10 Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
PCT/US2017/036521 WO2017214376A1 (en) 2016-06-10 2017-06-08 Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function

Publications (2)

Publication Number Publication Date
EP3469069A1 EP3469069A1 (en) 2019-04-17
EP3469069A4 true EP3469069A4 (en) 2020-01-22

Family

ID=60578909

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17811004.5A Withdrawn EP3469069A4 (en) 2016-06-10 2017-06-08 COMPOSITIONS AND METHODS WITH B-LYMPHOZYT CELL LINE EXPRESSING A DIFFERENT MEMBRANE IMMUNIZATION LOBULIN AS SECRETIED IMMUNOGLOBULIN, AND CYTOLYSIS FUNCTION

Country Status (3)

Country Link
EP (1) EP3469069A4 (en)
CN (1) CN109563482A (en)
WO (1) WO2017214376A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
CN112105641A (en) * 2018-03-19 2020-12-18 科塔生物治疗有限责任公司 Compositions and methods for modified B cell expression of redistributed biological agents
WO2020053865A1 (en) * 2018-09-13 2020-03-19 Ramot At Tel-Aviv University Ltd. Genetic engneering of b cell receptors and uses thereof in antigen-induced antibody secretion
KR20230006821A (en) * 2020-03-31 2023-01-11 워킹 피쉬 테라퓨틱스 Modified B cells and methods of use thereof
EP4127188A4 (en) * 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
WO2022051556A1 (en) * 2020-09-02 2022-03-10 Walking Fish Therapeutics Modified b cells and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071717A1 (en) * 2005-09-07 2007-03-29 University Of Iowa Research Foundation Treatment of B cells with IL-21 and B cell activators induces Granzyme B production
US20150283177A1 (en) * 2011-12-22 2015-10-08 Elwha Llc Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including at Least One Endogenous Gene Expressing at Least One Endogenous Membrane Immunoglobulin Reactive to a First Antigen and Including at Least One Exogenously Incorporated Nucleic Acid Expressing at Least One Exogenous Secreted Immunoglobulin Reactive to a Second Antigen
US20160355783A1 (en) * 2011-12-22 2016-12-08 Elwha Llc Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378A (en) 1850-05-21 John g
US276A (en) 1837-07-17 Horse-power
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5997859A (en) 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
DE4228162C1 (en) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Method for replacing homologous gene segments from mammals in the germline of non-human mammals
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
AU737155B2 (en) 1997-03-14 2001-08-09 Biogen Idec Inc. Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
KR20030038693A (en) * 2000-08-11 2003-05-16 파브릴, 인크. Method and Composition for Altering a B cell Mediated Pathology
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
JP4238138B2 (en) 2001-12-22 2009-03-11 ４−アンチボディ アーゲー Methods for the production of genetically modified vertebrate precursor lymphocytes and their use for the production of heterologous binding proteins.
ES2374068T3 (en) 2002-12-03 2012-02-13 Ucb Pharma, S.A. TEST TO IDENTIFY ANTIBODY PRODUCTION CELLS.
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
WO2005052139A2 (en) 2003-11-19 2005-06-09 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method of inducing memory b cell development and terminal differentiation
EP2316920A1 (en) * 2009-10-30 2011-05-04 BioNTech AG Clonal expansion of B cells
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071717A1 (en) * 2005-09-07 2007-03-29 University Of Iowa Research Foundation Treatment of B cells with IL-21 and B cell activators induces Granzyme B production
US20150283177A1 (en) * 2011-12-22 2015-10-08 Elwha Llc Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including at Least One Endogenous Gene Expressing at Least One Endogenous Membrane Immunoglobulin Reactive to a First Antigen and Including at Least One Exogenously Incorporated Nucleic Acid Expressing at Least One Exogenous Secreted Immunoglobulin Reactive to a Second Antigen
US20160355783A1 (en) * 2011-12-22 2016-12-08 Elwha Llc Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAGDALENA HAGN ET AL: "Why do human B cells secrete granzyme B? Insights into a novel B-cell differentiation pathway", ONCOIMMUNOLOGY, vol. 1, no. 8, 1 November 2012 (2012-11-01), pages 1368 - 1375, XP055449030, DOI: 10.4161/onci.22354 *
See also references of WO2017214376A1 *

Also Published As

Publication number Publication date
CN109563482A (en) 2019-04-02
WO2017214376A1 (en) 2017-12-14
EP3469069A1 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
EP3469069A4 (en) COMPOSITIONS AND METHODS WITH B-LYMPHOZYT CELL LINE EXPRESSING A DIFFERENT MEMBRANE IMMUNIZATION LOBULIN AS SECRETIED IMMUNOGLOBULIN, AND CYTOLYSIS FUNCTION
IL281059A (en) Methods for preparing chimeric antigen receptor-expressing cells
HUE046661T2 (en) SIRP-alpha immunoglobulin fusion proteins
IL263840A (en) cd3 binding antibodies
ZA201804514B (en) Bispecific t cell engaging antibody constructs
ZA201700488B (en) Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
IL257297A (en) Chimeric Antigen Receptors Based on Single-Site Antibodies and Methods for Using Them
LT3277321T (en) ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCINIC PROTEIN 3 (TIM-3)
PL4050034T3 (en) CD3 BINDING ANTIBODIES
LT3689140T (en) NON-HUMAN ANIMALS EXPRESSING HUMANIZED CD3 COMPLEX
EP3532489A4 (en) NEUTRALIZING MONOCLONAL ANTI-TL1A ANTIBODIES
PL3426686T3 (en) Humanized anti-pacap antibodies and uses thereof
MX2017015042A (en) Cd123 antibodies and conjugates thereof.
DK3455257T3 (en) ANTI-PD-L1 ANTIBODIES
DK3568810T3 (en) ACTION SELECTION FOR REINFORCEMENT LEARNING USING NEURAL NETWORKS
PT3247725T (en) ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BIESPECIFIC ANTIBODIES THAT BINDLY CONNECT TO CD3 AND / OR CD123
SI3016681T1 (en) Humanized or chimeric CD3 antibodies
DK3334457T3 (en) Humanized anti-CCR7 receptor antibodies
PT3286223T (en) KAPPA MYELOMA ANTIGEN CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
LT3491025T (en) FCRN ANTIBODIES AND THEIR USES
MA40901A (en) ANTI-TNF / ANTI-IL-3 BISPECIFIC ANTIBODIES
DE112015004443A5 (en) Photonically integrated chip, optical component with photonically integrated chip and method for its production
DK3430039T3 (en) ENGINEERED IMMUNOGLOBULINS WITH ALTERED FCRN BINDING
SG10202103120UA (en) Anti-coagulation factor xi antibodies
SG11201704160XA (en) Antibodies, uses & methods

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KOTA BIOTHERAPEUTICS, LLC

A4 Supplementary search report drawn up and despatched

Effective date: 20191220

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/17 20150101ALI20191216BHEP

Ipc: C12N 15/85 20060101ALI20191216BHEP

Ipc: C12N 5/0781 20100101AFI20191216BHEP

Ipc: A61K 35/12 20150101ALI20191216BHEP

Ipc: C07K 16/00 20060101ALI20191216BHEP

Ipc: A61K 38/17 20060101ALI20191216BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210608

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE INVENTION SCIENCE FUND II, LLC

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240522